Abstract:Tuberculosis (TB) remains a global health problem despite almost universal efforts to provide patients with highly effective chemotherapy, in part, because many infected individuals are not diagnosed and treated, others do not complete treatment, and a small proportion harbor Mycobacterium tuberculosis (Mtb ) strains that have become resistant to drugs in the standard regimen. Development and approval of new drugs for TB have accelerated in the last 10 years, but more drugs are needed due to both Mtb ’s development of resistance and the desire to shorten therapy to 4 months or less. The drug development process needs predictive animal models that recapitulate the complex pathology and bacterial burden distribution of human disease. The human host response to pulmonary infection with Mtb is granulomatous inflammation usually resulting in contained lesions and limited bacterial replication. In those who develop progressive or active disease, regions of necrosis and cavitation can develop leading to lasting lung damage and possible death. This review describes the major vertebrate animal models used in evaluating compound activity against Mtb and the disease presentation that develops. Each of the models, including the zebrafish, various mice, guinea pigs, rabbits, and non-human primates provides data on number of Mtb bacteria and pathology resolution. The models where individual lesions can be dissected from the tissue or sampled can also provide data on lesion-specific bacterial loads and lesion-specific drug concentrations. With the inclusion of medical imaging, a compound’s effect on resolution of pathology within individual lesions and animals can also be determined over time. Incorporation of measurement of drug exposure and drug distribution within animals and their tissues is important for choosing the best compounds to push toward the clinic and to the development of better regimens. We review the practical aspects of each model and the advantages and limitations of each in order to promote choosing a rational combination of them for a compound’s development.

Embryonic and larval zebrafish models for the discovery of new bioactive compounds against TB

Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis

Zebrafish Embryo Model for Assessment of Drug Efficacy on Mycobacterial Persisters

Diving into drug-screening: Zebrafish Embryos as an in vivo Platform for Antimicrobial Drug Discovery and Assessment

Integrating fish models in tuberculosis vaccine development

In vivo drug discovery in the zebrafish

One Size Fits All? Not in in Vivo Modeling of Tuberculosis Chemotherapeutics

Fishing for Drugs from Nature: Zebrafish as a Technology Platform for Natural Product Discovery

Zebrafish: An emerging model system to study liver diseases and related drug discovery

Potentiation of P2RX7 as a host-directed strategy for control of mycobacterial infection

The human pathogen Mycobacterium tuberculosis and the fish pathogen Mycobacterium marinum trigger the same core set of late innate immune response genes in zebrafish larvae

Zebrafish models for assessing developmental and reproductive toxicity

Application of zebrafish models in drug screening]

Mycobacterial FtsZ and inhibitors: a promising target for the anti-tubercular drug development

Zebrafish: An Emerging Model System for Human Disease and Drug Discovery

Zebrafish as tools for drug discovery

Zebrafish Model in Drug Safety Assessment

Zebrafish Embryos and Larvae as Alternative Animal Models for Toxicity Testing

Zebrafish As a Model System for Drug Target Screening and Validation

Integrated virtual screening and MD simulation study to discover potential inhibitors of mycobacterial electron transfer flavoprotein oxidoreductase

Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens